Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Fig. 1

Study overview (A) and comparison groups (B). IFOPA = International Fibrodysplasia Ossificans. Association, PET = Positrion Emission Tomography, CT = Computer Tomography, ROM = Range Of Motion

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us